Nuzenio

Tradingview Imrx

Tradingview Imrx entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 7 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Immuneering Corporation Stock 12‑Month Price Target Cut to $17.57, Implies 300% Upside - TradingViewTradingView · Thu, 06 Aug 2026 17:20:18 GMTImmuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 12:01:01 GMTIMRX: Phase 3 trial for atebimetinib launched; strong interim data and cash runway into 2029 - TradingViewTradingView · Wed, 05 Aug 2026 11:58:16 GMTIMRX: Advanced pivotal trial for atebimetinib, strong cash runway, and widened net loss on higher R&D - TradingViewTradingView · Wed, 05 Aug 2026 11:43:32 GMTImmuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingViewTradingView · Wed, 05 Aug 2026 11:43:03 GMTImmuneering expects cash runway to fund operations into 2029 - TradingViewTradingView · Wed, 05 Aug 2026 11:40:27 GMTIMRX Q2'26 Earnings: revenue estimate is 0 USD - TradingViewTradingView · Wed, 05 Aug 2026 11:00:17 GMT

Timeline

Thu, 06 Aug 2026 17:20:18 GMTImmuneering Corporation Stock 12‑Month Price Target Cut to $17.57, Implies 300% Upside - TradingView
Wed, 05 Aug 2026 12:01:01 GMTImmuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView
Wed, 05 Aug 2026 11:58:16 GMTIMRX: Phase 3 trial for atebimetinib launched; strong interim data and cash runway into 2029 - TradingView
Wed, 05 Aug 2026 11:43:32 GMTIMRX: Advanced pivotal trial for atebimetinib, strong cash runway, and widened net loss on higher R&D - TradingView
Wed, 05 Aug 2026 11:43:03 GMTImmuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingView
Wed, 05 Aug 2026 11:40:27 GMTImmuneering expects cash runway to fund operations into 2029 - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Imrx.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.